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See Article, pages 825–832Bacterial infections are frequent and represent a relevant issue in
cirrhotic patients. Susceptibility to bacterial infections is increased
in cirrhotic patients for multiple reasons. These patients show
immunological dysfunctions, due to the so called ‘‘immune paral-
ysis’’, and an impairment in the reticuloendothelial system func-
tion resulting in a reduced ability of the liver to contrast the
bacterial load from the intestine [1]. Moreover, they are predis-
posed to an increase in the rate and severity of ‘‘gut bacterial trans-
location’’ (GBT), deﬁned as themigration of viablemicroorganisms
and microbial products from the gut to mesenteric lymph nodes
and other extra intestinal sites. GBT appears to be related mainly
to three pathophysiological mechanisms: intestinal bacterial
overgrowth, due to decreased small bowel motility, increased
intestinal permeability, proportional to the degree of portal hyper-
tension, and impaired local and systemic immunity [2]. All these
factors are particularly evident in decompensated patients and
GBT is reported to occur in 30–40% of patients with ascites.
Infections are particularly harmful in advanced liver disease.
Decompensated cirrhotic patients suffering from a bacterial
infection are more prone to develop a systemic inﬂammatory
response syndrome [3]. In fact, hepatic dysfunction brings to a
decreased cytokine clearance capacity leading to a ‘‘storm of
pro-inﬂammatory mediators’’ (interleukin-1, interleukin-6,
tumor necrosis factor alpha), which causes the conversion of a
response normally useful against bacteria into a damaging
inﬂammation. This may induce an increased demand of acute-
phase-reaction proteins and an ‘‘exhaustion’’ of the hepatocytes
reserve function and further aggravation of the splanchnic vaso-
dilatation [4,5]. In cirrhotic patients sepsis may induce complica-
tions such as renal failure and hepatic encephalopathy. In
addition, the accelerated deterioration of liver function may lead
to the so called ‘‘acute on chronic liver failure’’. Severe sepsis may
also cause the development of ‘‘multiple organ failure’’ deﬁned by
at least two of the following: renal failure, acute lung injury or
acute respiratory distress syndrome, coagulopathy, brain failure,
sepsis-induced adrenal insufﬁciency and shock [6].
Bacterial infections and sepsis are one of the main causes of
death in hospitalized patients with chronic liver disease andJournal of Hepatology 20
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after the resolution of the infectious episode [7].
According to the hypothesis that the main mechanism in the
onset of infection is the GBT, the pathogens more frequently iso-
lated in cirrhotic patients are Gram-negative ones. Gram-positive
bacteria are also found mainly in nosocomial infections, due to
the large number of diagnostic and therapeutic invasive proce-
dures which are needed in hospitalized patient [8].
A relevant issue emerging in recent years is the change in the
epidemiological pattern of infections observed in cirrhotic
patients. In the course of their illness, cirrhotic patients are fre-
quently in need of day hospital care, recurrent hospitalization,
or admission in intensive care units. The classiﬁcation of infec-
tions in Community Acquired (CA) and Nosocomial (NA) has been
recently recognized to be inadequate in the general population,
and the term Health Care Related (HCR) infections, has been
introduced to deﬁne a new epidemiological category [9]. Accord-
ing to the proposal of Friedman and co-workers, an infection is
deﬁned HCR if the diagnosis is made within 48 h of hospitaliza-
tion in a patient with a recent contact with the Health Care
system (i.e. when the patient has attended a hospital or a hemod-
ialysis clinic, or has received intravenous chemotherapy during
the 30 days before infection; or was hospitalized for at least
2 days, or had undergone surgery during the 3 months before
infection; or has resided in a nursing home or a long-term care
facility) [9]. HCR infections are associated with an increased prev-
alence of antibiotic resistant bacteria, have a worse prognosis and
need to be treated according to different guidelines [10]. Recent
data underline the need to separately consider this epidemiolog-
ical group also in cirrhotic patients [11].
Antibiotic resistance in cirrhotic patients has been initially
feared due to the chronic use of quinolones in secondary prophy-
laxis for spontaneous bacterial peritonitis (SBP). However, it has
been clariﬁed that quinolones-resistant strains are still sensitive
to third generation cephalosporins (recommended ﬁrst line
therapy for SBP) [8,12]. A more relevant emerging problem in
cirrhotic patients is the increased prevalence of multidrug resis-
tant (MDR) bacteria, frequently isolated in the NA and HCR
groups. The deﬁnition of MDR pathogen includes methicillin-
resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii,
extended-spectrum beta-lactamases-producing Gram-negative
strains (ESBL), and any bacterial isolate resistant to at least
three classes of antimicrobial agents [13]. In our experience,12 vol. 56 j 756–757
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consecutive positive isolates from cirrhotic patients admitted in
our unit, which is a tertiary referral center, in the last year evi-
denced an increase in MDR pathogens mainly in HCR and NA
infections (33% in CA, 50% in NA and 80% in HCR; p = 0.0000) [14].
The more important types of infection in cirrhosis are urinary
tract infections, SBP, pneumonia and spontaneous bacteraemia
[3,11,15]. SBP is the most common infection in some series and
represents one of the most studied infections because of the
severe prognosis and high rate of recurrence [8]. The outcome
of PBS has improved signiﬁcantly over the past 30 years thanks
to an early diagnosis, and, especially, to the use of a more appro-
priate antibiotic therapy as suggested in current guidelines [16].
The paper of Ariza and co-workers [17] provides interesting
data about the prevalence of third generation cephalosporin
resistance (MR-Cef) in cirrhotic patients with a diagnosis of
SBP. The study is retrospective and analyzes 246 consecutive epi-
sodes of culture-positive SBP occurring in 200 cirrhotic patients
in a single Spanish center between 2001 and 2009. As the current
guidelines suggest the use of third generation cephalosporins for
the ﬁrst line empirical treatment of SBP, the authors evaluated
the appropriateness of this regimen and the predictors of failure.
The impact on mortality was also investigated. Some studies have
already drawn their attention on the reduced efﬁcacy of this ther-
apy in recent years [18,19].
The rate of MR-Cef was low in the group with CA infections
(7.1%), intermediate in the HCR (21.1%), and high in the NA
(40.9%), conﬁrming the link between bacterial resistance and
the epidemiology of infections. Previous use of cephalosporins,
upper gastrointestinal bleeding, nosocomial acquisition and dia-
betes were found to be independent predictors of MR-Cef. Fur-
thermore, the authors found a close association between the
days of contact with the health care system and the likelihood
of MR-Cef. A further important message coming from the study
of Ariza and co-workers is that, besides the other factors related
to the host condition, an inadequate empirical treatment of the
infection was an independent predictor of 30-day mortality.
Some shortcomings of the study need to be underlined. Due to
the retrospective design, the therapy was not properly standard-
ized in all patients; in particular, ceftriaxonewas utilized at a dose
of 1 g/24 h for 5–10 dayswhile the dosage recommended in guide-
lines is cefotaxime 4 g/day [13,20] corresponding to at least 2 g/
day of ceftriaxone. Therefore, some patients could have been
undertreated, causing a recurrence of SBP with MR-Cef strains. It
is also interesting to note that 39 patients, all in severe clinical
conditions, based on the physician decision, received piperacil-
lin–tazobactam or imipenem as ﬁrst line empirical therapy, deter-
mining a sort of ‘‘violation of the clinical protocol’’. All these
patients were classiﬁed as suffering from an HCR or a NA infection
and, in 36%, the cultures eventually resulted in MR-Cef strains. In
the statistical evaluation, the authors had to face this bias by
excluding some of these patients from the analysis of mortality.
This study underlines the need of prospective studies in cir-
rhotic patients with bacterial infections, taking care of the differ-
ent epidemiological conditions of bacterial acquisition. Different
antibiotic protocols need to be compared for their efﬁcacy and
costs in different patients’ settings to deﬁne, based on the evi-
dence, which is the most appropriate empiric antibiotic therapy
according to their risk factors. Therapeutic trials need also to be
extended to culture-negative SBP which frequently occurs in
cirrhotic patients, and to infections located at different sites.
Patients with long and multiple contact with the healthcareJournal of Hepatology 201system are at high risk of infections sustained by multi-drug
resistant strains and a change in the policy for the ﬁrst line
empirical antibiotic therapies in these patients is warranted.
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